1996 - Fellow of the American Statistical Association (ASA)
His scientific interests lie mostly in Internal medicine, Randomized controlled trial, Placebo, Estrogen and Physical therapy. His studies deal with areas such as Diabetes mellitus, Endocrinology and Cardiology as well as Internal medicine. His Randomized controlled trial research integrates issues from Clinical trial, Type 2 diabetes, Hazard ratio, Physical exercise and Pediatrics.
Mark A. Espeland has included themes like Corticosteroid, Asymptomatic, Hearing loss and Prednisone in his Placebo study. His Estrogen research is multidisciplinary, relying on both Hormone therapy, Gynecology and Menopause. As part of the same scientific family, Mark A. Espeland usually focuses on Physical therapy, concentrating on Weight loss and intersecting with Overweight, Research design and Physical fitness.
Mark A. Espeland focuses on Internal medicine, Gerontology, Randomized controlled trial, Cognition and Physical therapy. His Internal medicine research incorporates themes from Diabetes mellitus, Endocrinology, Type 2 diabetes and Cardiology. His study looks at the relationship between Type 2 diabetes and fields such as Obesity, as well as how they intersect with chemical problems.
His Gerontology research also works with subjects such as
Cognition, Internal medicine, Type 2 diabetes, Overweight and Gerontology are his primary areas of study. In his study, Glimepiride is inextricably linked to Linagliptin, which falls within the broad field of Internal medicine. His study with Type 2 diabetes involves better knowledge in Diabetes mellitus.
The concepts of his Overweight study are interwoven with issues in Odds ratio, Randomized controlled trial and Weight loss. His Weight loss research incorporates elements of Physical therapy, Incidence and Confidence interval. Mark A. Espeland combines subjects such as Intervention, Women's Health Initiative and Psychological intervention with his study of Gerontology.
The scientist’s investigation covers issues in Cognition, Dementia, Overweight, Internal medicine and Randomized controlled trial. The Cognition study combines topics in areas such as Affect, Gerontology and Risk factor. His Dementia research includes themes of Women's Health Initiative, Cognitive impairment and Clinical psychology.
His Overweight research is multidisciplinary, incorporating perspectives in Physical therapy, Type 2 diabetes, Pediatrics and Weight loss. His studies link Cardiology with Internal medicine. The study incorporates disciplines such as Metformin, Glimepiride and Linagliptin in addition to Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
Valery T. Miller;John LaRosa;Vanessa Barnabei;Craig Kessler.
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
R. R. Wing;P. Bolin;F. L. Brancati;G. A. Bray.
The New England Journal of Medicine (2013)
Sodium Reduction and Weight Loss in the Treatment of Hypertension in Older Persons: A Randomized Controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE)
Paul K. Whelton;Lawrence J. Appel;Mark A. Espeland;William B. Applegate.
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
Rena R. Wing;Judy L. Bahnson;George A. Bray;Jeanne M. Clark.
JAMA Internal Medicine (2010)
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial
Mark Espeland;Xavier Pi-Sunyer;George Blackburn;Frederick L. Brancati.
Diabetes Care (2007)
Effect of Structured Physical Activity on Prevention of Major Mobility Disability in Older Adults: The LIFE Study Randomized Clinical Trial
Marco Pahor;Jack M. Guralnik;Jack M. Guralnik;Walter T. Ambrosius;Steven Blair.
Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Stephen R. Rapp;Mark A. Espeland;Sally A. Shumaker;Victor W. Henderson.
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
C D Furberg;H P Adams;W B Applegate;R P Byington.
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.
Donna H Ryan;Mark A Espeland;Gary D Foster;Steven M Haffner.
Controlled Clinical Trials (2003)
Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study.
Timothy E. Craven;Jacqueline E. Ryu;Mark A. Espeland;Frederic R. Kahl.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: